ENSC · NASDAQ
Ensysce Biosciences (ENSC) Stock Price & Fundamentals
Ensysce Biosciences (ENSC) closed at $344.91 on Oct 9, 2026, down 0.61% from the previous close of $347.02.
Share price, past year
1Y +8.84%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $344.91 |
| Sep 30, 2026 | $337.84 |
| Aug 31, 2026 | $331.89 |
| Jul 31, 2026 | $312.22 |
| Jun 30, 2026 | $327.05 |
| May 29, 2026 | $334.74 |
| Apr 30, 2026 | $323.66 |
| Mar 31, 2026 | $308.36 |
| Feb 27, 2026 | $316.79 |
| Jan 30, 2026 | $320.94 |
| Dec 31, 2025 | $312.50 |
| Nov 28, 2025 | $325.96 |
| Oct 31, 2025 | $332.84 |
Key statistics
- Market cap
- $5.60B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.52
- Revenue (TTM)
- $4.50M
- Net income (TTM)
- —
- Shares outstanding
- 16.2M
- Dividend yield
- —
- 52-week range
- $303.36 – $349.83
Ensysce Biosciences's market cap is $5.60B, based on a share price of $344.91 and 16.2M shares outstanding as of Jun 30, 2026.
Financials
Ensysce Biosciences reported revenue of $5.07M for fiscal 2025, down 2.75% from fiscal 2024.
Ensysce Biosciences earned net income of $4.31M in fiscal 2020, a net margin of 109.7%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $5.07M | −2.8% | — | — | −$3.98 | −$7.93M |
| FY2024ended Dec 31, 2024 | $5.21M | +133.6% | — | — | −$11.45 | — |
| FY2023ended Dec 31, 2023 | $2.23M | −11.6% | — | — | −$70.40 | — |
| FY2022ended Dec 31, 2022 | $2.52M | −28.5% | — | — | −$139.42 | — |
| FY2021ended Dec 31, 2021 | $3.53M | −10.2% | — | — | −$1.48 | — |
| FY2020ended Dec 31, 2020 | $3.93M | — | $4.31M | 109.7% | $0.00 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.16M | — | −$0.20 |
| Q1 FY2026ended Mar 31, 2026 | $961.00K | — | −$0.52 |
| Q4 FY2025ended Dec 31, 2025 | $1.88M | — | −$0.51 |
| Q3 FY2025ended Sep 30, 2025 | $493.10K | — | −$1.29 |
| Q2 FY2025ended Jun 30, 2025 | $1.37M | — | −$0.79 |
| Q1 FY2025ended Mar 31, 2025 | $1.32M | — | −$1.39 |
| Q4 FY2024ended Dec 31, 2024 | $1.30M | — | −$0.89 |
| Q3 FY2024ended Sep 30, 2024 | $3.42M | — | $1.00 |
Company profile
- Name
- Ensysce Biosciences, Inc.
- Ticker
- ENSC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001716947
Recent SEC filings
- Sep 29, 2026
- Aug 25, 2026
- Aug 24, 2026
- Aug 13, 2026
- Aug 13, 2026
- Aug 6, 2026
- Jul 15, 2026
- May 22, 2026
Frequently asked questions
What is Ensysce Biosciences's stock price?
Ensysce Biosciences (ENSC) closed at $344.91 on Oct 9, 2026, down 0.61% from the previous close of $347.02.
What is Ensysce Biosciences's market cap?
Ensysce Biosciences's market cap is $5.60B, based on a share price of $344.91 and 16.2M shares outstanding as of Jun 30, 2026.
How much revenue does Ensysce Biosciences make?
Ensysce Biosciences reported revenue of $5.07M for fiscal 2025, down 2.75% from fiscal 2024.
Does Ensysce Biosciences pay a dividend?
Ensysce Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Ensysce Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures